Promising avelumab plus axitinib data in renal cell carcinoma

The following OncLive interview with leading renal cell carcinoma (RCC) expert, Dr Toni Choueiri from the Dana-Farber Cancer Institute in Boston, US, discusses the data from the JAVELIN-101 study comparing the avelumab/axitinib combination with sunitinib in patients with previously untreated RCC. Dr Choueiri goes on to discuss where these data fit into the complex treatment paradigm of […]

read more

ESMO 2018: Axitinib for the treatment of metastatic papillary renal cell carcinoma in the first-line

The results from a phase 2 clinical trial to assess the safety and efficacy of axinitib as a first-line treatment for patients with papillary renal cell carcinoma (pRCC) were presented at the European Society of Medical Oncology (ESMO) 2018 Congress in Munich over the weekend. The majority of renal cell carcinomas (RCCs) are a subtype […]

read more

Pembrolizumab plus axitinib combination promising as a first-line treatment for advanced RCC

Results from the KEYNOTE-426 phase 3 study show that the combination of the PD-1 inhibitor pembrolizumab (Keytruder) and the VEGF inhibitor axitinib (Inlyta) significantly improves progression-free survival versus sunitinib (Sutent) as a first-line treatment for advanced or metastatic renal cell carcinoma (RCC). A total of 861 untreated patients with advanced or metastatic RCC were randomly […]

read more

ESMO 2018: Avelumab plus axitinib combination shows great promise as first-line treatment for advanced RCC

Results from the JAVELIN Renal 101 phase 3 study to assess a combination of avelumab (Bavencio) and axitinib (Inlyta) versus sunitinib (Sutent) as first-line treatment for advanced renal cell carcinoma (RCC) were presented at the European Society of Medical Oncology (ESMO) 2018 conference in Munich over the weekend. Avelumab is a PD-L1 checkpoint inhibitor and […]

read more

ESMO 2018: Adjuvant axitinib versus placebo in patients at high risk of RCC recurrance

Results from the latest adjuvant study with a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), axitinib (Inlyta), were presented at the European Society of Medical Oncology (ESMO) 2018 conference in Munich over the weekend. Results of clinical trials assessing adjuvant therapy for intermediate- and high-risk renal cell carcinoma (RCC) with VEGF TKIs have […]

read more

Neoadjuvant axitinib shrinks kidney tumours to allow for partial nephrectomy

A recent phase II study of 18 patients with clear-cell renal cell carcinoma (RCC) stage cT2a showed that treatment with axitinib before surgery (neoadjuvant treatment) reduced the size of the tumour. Before treatment with axtinib, these patients were not considered suitable for partial nephrectomy. Neoadjuvant treatment with axitinib enabled 67% of patients to undergo partial nephrectomy […]

read more

Avelumab plus axitinib combination shows promise

A clinical trial looking at the combination of avelumab plus axitinib for renal cell carcinoma (RCC), JAVELIN Renal 101, has released some positive top-line results, which will be presented at an upcoming medical congress. JAVELIN Renal 101 is a pivotal phase III study with 886 renal cancer patients. As part of a planned interim analysis, […]

read more

Potential biomarkers may predict response to TKIs in metastatic kidney cancer

A recent study published in Clinical Cancer Research and conducted in France has identified potential biological markers that are related to the formation of new blood vessels (angiogenesis) and regulated by the levels of oxygen reaching the tissues (hypoxia). These biomarkers have been found to be strong predictors of response, progression-free survival (PFS), and overall survival […]

read more

Axitinib for metastatic non-clear cell renal cell carcinoma

Results from a phase 2 clinical trial of axitinib (Inlyta) for patients with advanced non-clear cell renal cell carcinoma (RCC) who had failed prior treatment with temsirolimus (Torisel) are promising in terms of objective response rate (ORR) and progression-free survival (PFS).  Forty patients with metastatic or recurrent non-clear cell RCC who had failed treatment with […]

read more

Avelumab plus axitinib combination effective in the first-line but with unfavourable side effects

Safety results from a phase 1b dose-finding and dose expansion study for the avelumab plus axitinib combination in untreated (treatment-naive) renal cell carcinoma (RCC) patients were published in the journal Lancet Oncology recently. Headline results from this study were previously reported at the American Society of Clinical Oncology (ASCO) annual meeting in June last year (2017), […]

read more
Showing 41 to 50 of 65 results
  TOP